Brain Grant Reviews Locked Away from Prying Eyes
Published Date: 6/18/2025
Notice
Summary
The National Institute of Neurological Disorders and Stroke is holding a closed meeting on August 7, 2025, to review and decide on grant applications. This affects researchers seeking funding for brain and nerve disorder studies. The meeting keeps sensitive info private and helps decide who gets money to push science forward.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
NINDS Closed Grant Review Meeting
The National Institute of Neurological Disorders and Stroke (NINDS) will hold a closed meeting on August 7, 2025, from 1:30 p.m. to 4:00 p.m. to review and evaluate grant applications. The meeting will be closed to the public to protect confidential trade secrets, patentable material, and personal information of applicants; it is held at NIH (6001 Executive Boulevard, Rockville, MD) as a virtual meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2025-11255, Fogarty International Center; Notice of Meeting
The Fogarty International Center Advisory Board is meeting on September 4-5, 2025, to review grant applications and discuss current and future projects. The first day includes a private session to evaluate grants, while the second day is open to the public both in-person and online. This meeting affects researchers seeking funding and anyone interested in global health, with no direct cost changes announced.
Next: 2025-11258, Clean Air Act Prevention of Significant Deterioration Permit Revision Issued to South Point Energy, LLC, for the South Point Energy Center
The EPA just gave South Point Energy Center the green light to upgrade and run two of their natural gas turbines. This means cleaner, more efficient energy without breaking air quality rules. These changes help South Point keep things running smoothly while protecting the air we all breathe.